An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension.

Trial Profile

An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Aliskiren; Amlodipine
  • Indications Essential hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 12 Jun 2012 Actual patient number changed from 944 to 1342 as reported by ClincialTrials.gov (Parent trial: NCT01237223).
    • 25 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov (NCT01237223).
    • 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT01237223).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top